PUBLISHER: Acute Market Reports | PRODUCT CODE: 1557761
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1557761
Genitourinary Drugs Market - Growth, Future Prospects and Competitive Analysis, 2024 - 2032
The genitourinary drugs market is expected to grow at a CAGR of 2.2% during the forecast period of 2024 to 2032. Genitourinary drugs market encompasses a range of pharmaceuticals used to treat disorders affecting the urinary tract and the male and female reproductive systems. These conditions include urinary tract infections, erectile dysfunction, renal diseases, bladder cancer, and chronic kidney disease, among others. The market is characterized by a robust pipeline of pharmacological innovations and is driven by increasing prevalence of related diseases, advancements in medical treatments, and rising awareness and healthcare spending globally. As populations age and more emphasis is placed on quality of life and longevity, demand for genitourinary drugs continues to grow, providing substantial opportunities for market expansion.
Key Drivers of the genitourinary drugs market
Rising Prevalence of Genitourinary Disorders
The growing global burden of genitourinary disorders is a significant driver of the market. With the aging of the population worldwide, diseases such as erectile dysfunction, urinary incontinence, and chronic kidney disease are becoming more common. For instance, the prevalence of benign prostatic hyperplasia (BPH), a common condition affecting elderly men, is increasing with the aging population. This rise in prevalence directly translates into heightened demand for treatments, particularly drugs that can alleviate symptoms and manage the conditions long-term. Furthermore, the global increase in diabetes and hypertension - key risk factors for chronic kidney disease - also expands the patient pool requiring genitourinary drugs, thereby propelling market growth.
Technological Advancements in Drug Development
Technological advancements in drug development significantly drive the genitourinary drugs market. Recent years have seen notable improvements in the pharmacological management of genitourinary conditions, including the development of drugs with better efficacy and fewer side effects. For example, the introduction of PDE5 inhibitors revolutionized the treatment of erectile dysfunction, offering patients effective and minimally invasive treatment options. Additionally, biotechnological advancements have enabled the development of biologic drugs that target specific pathways involved in diseases like overactive bladder and interstitial cystitis, providing more effective treatment options and boosting market growth. The ongoing investment in R&D, fueled by the high potential for profitability in this sector, continues to yield innovative products that meet the evolving needs of patients.
Increased Healthcare Spending and Insurance Coverage
Increased healthcare spending and improvements in insurance coverage are crucial in driving the adoption of genitourinary drugs. As healthcare systems worldwide become more robust and accessible, more patients are able to seek treatment for conditions that were previously stigmatized or not prioritized, such as sexual health issues and incontinence. The expansion of healthcare insurance coverage, including Medicare and Medicaid in the United States, has also played a vital role in increasing access to necessary medications. This expansion ensures that a larger segment of the population can afford these often expensive treatments, thereby increasing market penetration and driving growth in the genitourinary drugs sector.
Market Restraint
High Cost of Drug Development and Risk of Failure
A major restraint in the genitourinary drugs market is the high cost associated with drug development coupled with a significant risk of failure. Developing new pharmaceuticals for genitourinary conditions involves extensive research and multiple phases of clinical trials, which are both time-consuming and costly. The investment required to bring a new drug to market can reach billions of dollars, and the risk of clinical failure remains high, with many compounds failing to demonstrate efficacy or safety required for regulatory approval. This high cost and risk deter some pharmaceutical companies from investing in the development of drugs for less common genitourinary conditions, thereby limiting the availability of treatments for these diseases and restraining market growth. Despite the lucrative potential of the market, these economic and operational challenges pose significant barriers to entry and innovation within the field.
Market Segmentation by Drug Type
The genitourinary drugs market is segmented by drug type into hormonal therapy, anti-infective, and other drug types. Hormonal therapy, particularly for conditions like prostate cancer and hormone-responsive bladder cancer, consistently generates the highest revenue within the market. This segment benefits from the strong prevalence of hormone-related disorders in the aging population, coupled with ongoing advancements in hormone therapies that improve efficacy and patient adherence. However, the anti-infective segment is anticipated to exhibit the highest CAGR due to increasing resistance to conventional antibiotics and the rising incidence of urinary tract infections (UTIs) globally. This growth is driven by continuous developments in next-generation anti-infectives, which are more effective against resistant strains of bacteria commonly implicated in genitourinary infections. The expanding research focus and funding for combating antimicrobial resistance are crucial factors propelling this segment.
Market Segmentation by Application
In terms of application, the genitourinary drugs market serves several conditions, including urinary tract infections (UTIs), benign prostatic hyperplasia (BPH), prostate cancer, overactive bladder, bladder cancer, and other applications. The segment addressing BPH accounts for the highest revenue, driven by the high prevalence of the condition among older male populations worldwide and the chronic nature of the disease, which requires long-term drug management. BPH treatments have evolved, but the mainstay continues to be drug therapies that reduce the size of the prostate and alleviate urinary symptoms, thus ensuring sustained market demand. Conversely, the prostate cancer segment is expected to witness the highest CAGR from innovations in targeted therapies and hormonal treatments that offer improved survival rates and quality of life for patients. This segment's growth is accelerated by increasing global awareness and screening practices that lead to early diagnosis, where pharmacological interventions can be most effective, underscoring the dynamic expansion in this market area.
Geographic Trends in the Genitourinary Drugs Market
The genitourinary drugs market exhibits significant geographic variation in growth dynamics and revenue generation. North America holds the largest revenue share, attributed to its well-established healthcare infrastructure, high healthcare expenditure, and the presence of a large aging population suffering from various genitourinary conditions. This region's dominance is further reinforced by aggressive health policy initiatives that promote early screening and diagnosis, comprehensive insurance coverage, and substantial investments in drug development. Meanwhile, the Asia-Pacific region is anticipated to exhibit the highest CAGR from 2024 to 2032. This surge is driven by rapidly improving healthcare facilities, increasing awareness of genitourinary disorders, growing healthcare budgets, and expanding access to medical treatments in populous countries like China and India. The rising prevalence of lifestyle-related health issues, such as diabetes and hypertension, which are risk factors for diseases like chronic kidney disease and bladder dysfunction, also contribute to this growth. Additionally, the expanding middle class in this region increasingly demands higher quality healthcare solutions, further propelling the market for genitourinary drugs.
Competitive Trends and Key Strategies
The competitive landscape of the genitourinary drugs market is shaped by the activities of major players such as Abbott Laboratories, Allergan, Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Ionis Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd. In 2022, these companies reported substantial revenues stemming from their genitourinary portfolios, showcasing the significant market presence and impact of their products. For instance, companies like Pfizer and AstraZeneca have benefited from strong sales of drugs used in the treatment of prostate and bladder cancers, reflecting their strategic focus on oncology. From 2024 to 2032, the market is expected to witness enhanced competitive dynamics as companies increase investment in innovative drug development to address unmet medical needs in the genitourinary sector. Strategies such as mergers and acquisitions are anticipated to remain prevalent, allowing companies to expand their product ranges and enter new geographic markets. For example, collaborations between companies like Eli Lilly and smaller biotech firms are expected to foster the development of novel therapeutic agents, including those based on genetic therapies and molecular diagnostics. Additionally, there is an expected increase in strategic partnerships with academic institutions and research organizations to advance research on complex urogenital disorders, thereby speeding up drug discovery and clinical trials. The emphasis on sustainability and patient-centric approaches in drug development and marketing is also likely to shape the strategic landscape, reflecting a broader industry trend towards personalized medicine and value-based healthcare.
Historical & Forecast Period
This study report represents an analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Genitourinary Drugs market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users & consumption volume, price, and value.
Geographical revenues generated by countries considered in the report
Micro and macro environment factors that are currently influencing the Genitourinary Drugs market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.
Market Segmentation
Drug Type
- Hormonal therapy
- Androgen
- Estrogen
- Other hormonal therapy
- Anti-infective
- Antibiotics
- Antifungals
- Antivirals
- Other drug types
Application
- Urinary tract infections (UTIs)
- Benign prostatic hyperplasia (BPH)
- Prostate cancer
- Overactive bladder
- Bladder cancer
- Other applications
Route of Administration
- Oral
- Parenteral
- Topical
Distribution Channel
- Hospital pharmacies
- Drug store & retail pharmacies
- Online pharmacies
Region Segment (2022-2032; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Key questions answered in this report
What are the key micro and macro environmental factors that are impacting the growth of Genitourinary Drugs market?
What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2032.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Genitourinary Drugs market?
Which is the largest regional market for Genitourinary Drugs market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Genitourinary Drugs market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Genitourinary Drugs market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Genitourinary Drugs Market
- 2.2. Global Genitourinary Drugs Market, By Drug Type, 2023 (US$ Million)
- 2.3. Global Genitourinary Drugs Market, By Application, 2023 (US$ Million)
- 2.4. Global Genitourinary Drugs Market, By Route of Administration, 2023 (US$ Million)
- 2.5. Global Genitourinary Drugs Market, By Distribution Channel, 2023 (US$ Million)
- 2.6. Global Genitourinary Drugs Market, By Geography, 2023 (US$ Million)
- 2.7. Attractive Investment Proposition by Geography, 2023
3. Genitourinary Drugs Market: Competitive Analysis
- 3.1. Market Positioning of Key Genitourinary Drugs Market Vendors
- 3.2. Strategies Adopted by Genitourinary Drugs Market Vendors
- 3.3. Key Industry Strategies
4. Genitourinary Drugs Market: Macro Analysis & Market Dynamics
- 4.1. Introduction
- 4.2. Global Genitourinary Drugs Market Value, 2022 - 2032, (US$ Million)
- 4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
- 4.4. Impact Analysis of Drivers and Restraints
- 4.5. See-Saw Analysis
- 4.6. Porter's Five Force Model
- 4.6.1. Supplier Power
- 4.6.2. Buyer Power
- 4.6.3. Threat Of Substitutes
- 4.6.4. Threat Of New Entrants
- 4.6.5. Competitive Rivalry
- 4.7. PESTEL Analysis
- 4.7.1. Political Landscape
- 4.7.2. Economic Landscape
- 4.7.3. Technology Landscape
- 4.7.4. Legal Landscape
- 4.7.5. Social Landscape
5. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2023 Versus 2032
- 5.3. Market Segmentation
- 5.3.1. Hormonal therapy
- 5.3.1.1. Androgen
- 5.3.1.2. Estrogen
- 5.3.1.3. Other hormonal therapy
- 5.3.2. Anti-infective
- 5.3.2.1. Antibiotics
- 5.3.2.2. Antifungals
- 5.3.2.3. Antivirals
- 5.3.3. Other drug types
- 5.3.1. Hormonal therapy
6. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 6.1. Market Overview
- 6.2. Growth & Revenue Analysis: 2023 Versus 2032
- 6.3. Market Segmentation
- 6.3.1. Urinary tract infections (UTIs)
- 6.3.2. Benign prostatic hyperplasia (BPH)
- 6.3.3. Prostate cancer
- 6.3.4. Overactive bladder
- 6.3.5. Bladder cancer
- 6.3.6. Other applications
7. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 7.1. Market Overview
- 7.2. Growth & Revenue Analysis: 2023 Versus 2032
- 7.3. Market Segmentation
- 7.3.1. Oral
- 7.3.2. Parenteral
- 7.3.3. Topical
8. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.1. Market Overview
- 8.2. Growth & Revenue Analysis: 2023 Versus 2032
- 8.3. Market Segmentation
- 8.3.1. Hospital pharmacies
- 8.3.2. Drug store & retail pharmacies
- 8.3.3. Online pharmacies
9. North America Genitourinary Drugs Market, 2022-2032, USD (Million)
- 9.1. Market Overview
- 9.2. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 9.3. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 9.4. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 9.5. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.6.Genitourinary Drugs Market: By Region, 2022-2032, USD (Million)
- 9.6.1.North America
- 9.6.1.1. U.S.
- 9.6.1.1.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 9.6.1.1.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 9.6.1.1.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 9.6.1.1.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.6.1.2. Canada
- 9.6.1.2.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 9.6.1.2.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 9.6.1.2.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 9.6.1.2.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.6.1.3. Rest of North America
- 9.6.1.3.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 9.6.1.3.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 9.6.1.3.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 9.6.1.3.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.6.1.1. U.S.
- 9.6.1.North America
10. UK and European Union Genitourinary Drugs Market, 2022-2032, USD (Million)
- 10.1. Market Overview
- 10.2. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 10.3. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 10.4. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 10.5. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.6.Genitourinary Drugs Market: By Region, 2022-2032, USD (Million)
- 10.6.1.UK and European Union
- 10.6.1.1. UK
- 10.6.1.1.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 10.6.1.1.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 10.6.1.1.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 10.6.1.1.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.6.1.2. Germany
- 10.6.1.2.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 10.6.1.2.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 10.6.1.2.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 10.6.1.2.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.6.1.3. Spain
- 10.6.1.3.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 10.6.1.3.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 10.6.1.3.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 10.6.1.3.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.6.1.4. Italy
- 10.6.1.4.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 10.6.1.4.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 10.6.1.4.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 10.6.1.4.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.6.1.5. France
- 10.6.1.5.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 10.6.1.5.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 10.6.1.5.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 10.6.1.5.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.6.1.6. Rest of Europe
- 10.6.1.6.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 10.6.1.6.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 10.6.1.6.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 10.6.1.6.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.6.1.1. UK
- 10.6.1.UK and European Union
11. Asia Pacific Genitourinary Drugs Market, 2022-2032, USD (Million)
- 11.1. Market Overview
- 11.2. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 11.3. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 11.4. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 11.5. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.6.Genitourinary Drugs Market: By Region, 2022-2032, USD (Million)
- 11.6.1.Asia Pacific
- 11.6.1.1. China
- 11.6.1.1.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 11.6.1.1.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 11.6.1.1.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 11.6.1.1.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.6.1.2. Japan
- 11.6.1.2.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 11.6.1.2.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 11.6.1.2.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 11.6.1.2.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.6.1.3. India
- 11.6.1.3.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 11.6.1.3.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 11.6.1.3.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 11.6.1.3.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.6.1.4. Australia
- 11.6.1.4.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 11.6.1.4.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 11.6.1.4.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 11.6.1.4.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.6.1.5. South Korea
- 11.6.1.5.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 11.6.1.5.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 11.6.1.5.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 11.6.1.5.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.6.1.6. Rest of Asia Pacific
- 11.6.1.6.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 11.6.1.6.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 11.6.1.6.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 11.6.1.6.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.6.1.1. China
- 11.6.1.Asia Pacific
12. Latin America Genitourinary Drugs Market, 2022-2032, USD (Million)
- 12.1. Market Overview
- 12.2. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 12.3. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 12.4. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 12.5. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 12.6.Genitourinary Drugs Market: By Region, 2022-2032, USD (Million)
- 12.6.1.Latin America
- 12.6.1.1. Brazil
- 12.6.1.1.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 12.6.1.1.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 12.6.1.1.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 12.6.1.1.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 12.6.1.2. Mexico
- 12.6.1.2.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 12.6.1.2.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 12.6.1.2.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 12.6.1.2.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 12.6.1.3. Rest of Latin America
- 12.6.1.3.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 12.6.1.3.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 12.6.1.3.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 12.6.1.3.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 12.6.1.1. Brazil
- 12.6.1.Latin America
13. Middle East and Africa Genitourinary Drugs Market, 2022-2032, USD (Million)
- 13.1. Market Overview
- 13.2. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 13.3. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 13.4. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 13.5. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 13.6.Genitourinary Drugs Market: By Region, 2022-2032, USD (Million)
- 13.6.1.Middle East and Africa
- 13.6.1.1. GCC
- 13.6.1.1.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 13.6.1.1.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 13.6.1.1.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 13.6.1.1.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 13.6.1.2. Africa
- 13.6.1.2.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 13.6.1.2.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 13.6.1.2.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 13.6.1.2.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 13.6.1.3. Rest of Middle East and Africa
- 13.6.1.3.1. Genitourinary Drugs Market: By Drug Type, 2022-2032, USD (Million)
- 13.6.1.3.2. Genitourinary Drugs Market: By Application, 2022-2032, USD (Million)
- 13.6.1.3.3. Genitourinary Drugs Market: By Route of Administration, 2022-2032, USD (Million)
- 13.6.1.3.4. Genitourinary Drugs Market: By Distribution Channel, 2022-2032, USD (Million)
- 13.6.1.1. GCC
- 13.6.1.Middle East and Africa
14. Company Profile
- 14.1. Abbott Laboratories
- 14.1.1. Company Overview
- 14.1.2. Financial Performance
- 14.1.3. Product Portfolio
- 14.1.4. Strategic Initiatives
- 14.2. Allergan, Inc.
- 14.2.1. Company Overview
- 14.2.2. Financial Performance
- 14.2.3. Product Portfolio
- 14.2.4. Strategic Initiatives
- 14.3. AstraZeneca Plc
- 14.3.1. Company Overview
- 14.3.2. Financial Performance
- 14.3.3. Product Portfolio
- 14.3.4. Strategic Initiatives
- 14.4. Bayer AG
- 14.4.1. Company Overview
- 14.4.2. Financial Performance
- 14.4.3. Product Portfolio
- 14.4.4. Strategic Initiatives
- 14.5. Bristol-Myers Squibb Co.
- 14.5.1. Company Overview
- 14.5.2. Financial Performance
- 14.5.3. Product Portfolio
- 14.5.4. Strategic Initiatives
- 14.6. Eli Lilly and Company
- 14.6.1. Company Overview
- 14.6.2. Financial Performance
- 14.6.3. Product Portfolio
- 14.6.4. Strategic Initiatives
- 14.7. F. Hoffmann-La Roche Ltd.
- 14.7.1. Company Overview
- 14.7.2. Financial Performance
- 14.7.3. Product Portfolio
- 14.7.4. Strategic Initiatives
- 14.8. GlaxoSmithKline Plc
- 14.8.1. Company Overview
- 14.8.2. Financial Performance
- 14.8.3. Product Portfolio
- 14.8.4. Strategic Initiatives
- 14.9. Ionis Pharmaceuticals, Inc.
- 14.9.1. Company Overview
- 14.9.2. Financial Performance
- 14.9.3. Product Portfolio
- 14.9.4. Strategic Initiatives
- 14.10. Merck & Co., Inc.
- 14.10.1. Company Overview
- 14.10.2. Financial Performance
- 14.10.3. Product Portfolio
- 14.10.4. Strategic Initiatives
- 14.11. Novartis AG
- 14.11.1. Company Overview
- 14.11.2. Financial Performance
- 14.11.3. Product Portfolio
- 14.11.4. Strategic Initiatives
- 14.12. Pfizer, Inc.
- 14.12.1. Company Overview
- 14.12.2. Financial Performance
- 14.12.3. Product Portfolio
- 14.12.4. Strategic Initiatives
- 14.13. Teva Pharmaceutical Industries Ltd
- 14.13.1. Company Overview
- 14.13.2. Financial Performance
- 14.13.3. Product Portfolio
- 14.13.4. Strategic Initiatives
- 14.14. Other Notable Players
- 14.14.1. Company Overview
- 14.14.2. Financial Performance
- 14.14.3. Product Portfolio
- 14.14.4. Strategic Initiatives
List of Tables
- TABLE 1 Global Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 2 Global Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 3 Global Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 4 Global Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 5 Global Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 6 Global Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 7 North America Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 8 North America Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 9 North America Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 10 North America Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 11 North America Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 12 North America Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 13 U.S. Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 14 U.S. Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 15 U.S. Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 16 U.S. Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 17 U.S. Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 18 U.S. Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 19 Canada Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 20 Canada Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 21 Canada Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 22 Canada Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 23 Canada Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 24 Canada Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 25 Rest of North America Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 26 Rest of North America Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 27 Rest of North America Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 28 Rest of North America Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 29 Rest of North America Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 30 Rest of North America Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 31 UK and European Union Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 32 UK and European Union Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 33 UK and European Union Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 34 UK and European Union Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 35 UK and European Union Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 36 UK and European Union Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 37 UK Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 38 UK Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 39 UK Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 40 UK Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 41 UK Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 42 UK Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 43 Germany Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 44 Germany Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 45 Germany Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 46 Germany Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 47 Germany Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 48 Germany Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 49 Spain Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 50 Spain Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 51 Spain Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 52 Spain Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 53 Spain Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 54 Spain Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 55 Italy Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 56 Italy Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 57 Italy Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 58 Italy Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 59 Italy Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 60 Italy Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 61 France Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 62 France Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 63 France Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 64 France Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 65 France Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 66 France Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 67 Rest of Europe Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 68 Rest of Europe Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 69 Rest of Europe Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 70 Rest of Europe Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 71 Rest of Europe Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 72 Rest of Europe Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 73 Asia Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 74 Asia Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 75 Asia Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 76 Asia Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 77 Asia Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 78 Asia Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 79 China Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 80 China Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 81 China Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 82 China Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 83 China Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 84 China Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 85 Japan Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 86 Japan Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 87 Japan Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 88 Japan Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 89 Japan Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 90 Japan Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 91 India Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 92 India Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 93 India Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 94 India Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 95 India Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 96 India Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 97 Australia Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 98 Australia Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 99 Australia Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 100 Australia Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 101 Australia Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 102 Australia Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 103 South Korea Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 104 South Korea Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 105 South Korea Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 106 South Korea Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 107 South Korea Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 108 South Korea Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 109 Latin America Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 110 Latin America Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 111 Latin America Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 112 Latin America Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 113 Latin America Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 114 Latin America Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 115 Brazil Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 116 Brazil Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 117 Brazil Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 118 Brazil Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 119 Brazil Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 120 Brazil Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 121 Mexico Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 122 Mexico Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 123 Mexico Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 124 Mexico Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 125 Mexico Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 126 Mexico Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 127 Rest of Latin America Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 128 Rest of Latin America Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 129 Rest of Latin America Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 130 Rest of Latin America Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 131 Rest of Latin America Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 132 Rest of Latin America Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 133 Middle East and Africa Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 134 Middle East and Africa Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 135 Middle East and Africa Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 136 Middle East and Africa Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 137 Middle East and Africa Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 138 Middle East and Africa Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 139 GCC Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 140 GCC Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 141 GCC Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 142 GCC Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 143 GCC Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 144 GCC Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 145 Africa Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 146 Africa Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 147 Africa Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 148 Africa Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 149 Africa Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 150 Africa Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 151 Rest of Middle East and Africa Genitourinary Drugs Market By Drug Type, 2022-2032, USD (Million)
- TABLE 152 Rest of Middle East and Africa Genitourinary Drugs Market By Hormonal therapy, 2022-2032, USD (Million)
TABLE 153 Rest of Middle East and Africa Genitourinary Drugs Market By Anti-infective, 2022-2032, USD (Million)
TABLE 154 Rest of Middle East and Africa Genitourinary Drugs Market By Application, 2022-2032, USD (Million)
- TABLE 155 Rest of Middle East and Africa Genitourinary Drugs Market By Route of Administration, 2022-2032, USD (Million)
- TABLE 156 Rest of Middle East and Africa Genitourinary Drugs Market By Distribution Channel, 2022-2032, USD (Million)
List of Figures
- FIG. 1 Global Genitourinary Drugs Market: Market Coverage
- FIG. 2 Research Methodology and Data Sources
- FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
- FIG. 4 Global Genitourinary Drugs Market: Quality Assurance
- FIG. 5 Global Genitourinary Drugs Market, By Drug Type, 2023
- FIG. 6 Global Genitourinary Drugs Market, By Application, 2023
- FIG. 7 Global Genitourinary Drugs Market, By Route of Administration, 2023
- FIG. 8 Global Genitourinary Drugs Market, By Distribution Channel, 2023
- FIG. 9 Global Genitourinary Drugs Market, By Geography, 2023
- FIG. 10 Market Geographical Opportunity Matrix - Global Genitourinary Drugs Market, 2023
FIG. 11Market Positioning of Key Genitourinary Drugs Market Players, 2023
FIG. 12Global Genitourinary Drugs Market - Tier Analysis - Percentage of Revenues by Tier Level, 2023 Versus 2032
- FIG. 13 Global Genitourinary Drugs Market, By Drug Type, 2023 Vs 2032, %
- FIG. 14 Global Genitourinary Drugs Market, By Application, 2023 Vs 2032, %
- FIG. 15 Global Genitourinary Drugs Market, By Route of Administration, 2023 Vs 2032, %
- FIG. 16 Global Genitourinary Drugs Market, By Distribution Channel, 2023 Vs 2032, %
- FIG. 17 U.S. Genitourinary Drugs Market (US$ Million), 2022 - 2032
- FIG. 18 Canada Genitourinary Drugs Market (US$ Million), 2022 - 2032
- FIG. 19 Rest of North America Genitourinary Drugs Market (US$ Million), 2022 - 2032
- FIG. 20 UK Genitourinary Drugs Market (US$ Million), 2022 - 2032
- FIG. 21 Germany Genitourinary Drugs Market (US$ Million), 2022 - 2032
- FIG. 22 Spain Genitourinary Drugs Market (US$ Million), 2022 - 2032
- FIG. 23 Italy Genitourinary Drugs Market (US$ Million), 2022 - 2032
- FIG. 24 France Genitourinary Drugs Market (US$ Million), 2022 - 2032
- FIG. 25 Rest of Europe Genitourinary Drugs Market (US$ Million), 2022 - 2032
- FIG. 26 China Genitourinary Drugs Market (US$ Million), 2022 - 2032
- FIG. 27 Japan Genitourinary Drugs Market (US$ Million), 2022 - 2032
- FIG. 28 India Genitourinary Drugs Market (US$ Million), 2022 - 2032
- FIG. 29 Australia Genitourinary Drugs Market (US$ Million), 2022 - 2032
- FIG. 30 South Korea Genitourinary Drugs Market (US$ Million), 2022 - 2032
- FIG. 31 Rest of Asia Genitourinary Drugs Market (US$ Million), 2022 - 2032
- FIG. 32 Brazil Genitourinary Drugs Market (US$ Million), 2022 - 2032
- FIG. 33 Mexico Genitourinary Drugs Market (US$ Million), 2022 - 2032
- FIG. 34 Rest of Latin America Genitourinary Drugs Market (US$ Million), 2022 - 2032
- FIG. 35 GCC Genitourinary Drugs Market (US$ Million), 2022 - 2032
- FIG. 36 Africa Genitourinary Drugs Market (US$ Million), 2022 - 2032
- FIG. 37 Rest of Middle East and Africa Genitourinary Drugs Market (US$ Million), 2022 - 2032
